VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

CONy 2022 | Progress in the management of non-motor symptoms of Parkinson’s disease

Heinz Reichmann, MD, PhD, University of Dresden, Dresden, Germany, discusses the management of non-motor symptoms in Parkinson’s disease (PD), particularly impulse-control disorders, a class of psychiatric disorders characterized by impulsivity and primarily associated in PD patients with dopamine agonists use. High doses of dopamine agonists can cause hypersexuality, gambling, and other features that impact patients’ quality of life and are destructive to caregivers. Therefore, impulse control disorders are very important to consider. Meanwhile, long-acting dopamine agonists can help non-motor symptoms such as mood disturbances, cognitive decline, constipation, loss of smell, and sleep problems. Advances in the availability of novel treatments have improved the management of non-motor symptoms. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.

Disclosures

Prof. Reichmann was acting on Advisory Boards and gave lectures and received research grants within the last 5 years from Bial, Desitin, Eisai, Kyowa-Kirin, Merz, Novartis, UCB Pharma, Zambon.